Nordea Investment Management AB Sells 68,527 Shares of Elevance Health, Inc. $ELV

Nordea Investment Management AB trimmed its position in shares of Elevance Health, Inc. (NYSE:ELV) by 16.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 340,267 shares of the company’s stock after selling 68,527 shares during the quarter. Nordea Investment Management AB owned 0.15% of Elevance Health worth $119,420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Evergreen Wealth Management LLC boosted its position in Elevance Health by 33.5% in the third quarter. Evergreen Wealth Management LLC now owns 17,283 shares of the company’s stock worth $5,584,000 after purchasing an additional 4,336 shares during the last quarter. Blume Capital Management Inc. increased its position in shares of Elevance Health by 236.7% during the 3rd quarter. Blume Capital Management Inc. now owns 6,145 shares of the company’s stock valued at $1,986,000 after purchasing an additional 4,320 shares during the last quarter. Canoe Financial LP raised its stake in shares of Elevance Health by 18.1% during the 3rd quarter. Canoe Financial LP now owns 389,399 shares of the company’s stock worth $125,823,000 after purchasing an additional 59,743 shares during the period. Synergy Asset Management LLC raised its stake in shares of Elevance Health by 100.0% during the 3rd quarter. Synergy Asset Management LLC now owns 104,334 shares of the company’s stock worth $33,712,000 after purchasing an additional 52,167 shares during the period. Finally, Victory Capital Management Inc. boosted its holdings in shares of Elevance Health by 31.1% in the 3rd quarter. Victory Capital Management Inc. now owns 461,693 shares of the company’s stock worth $149,182,000 after buying an additional 109,462 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

NYSE ELV opened at $291.90 on Monday. The firm has a market cap of $64.43 billion, a P/E ratio of 11.62, a price-to-earnings-growth ratio of 1.60 and a beta of 0.51. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70. The company’s 50 day moving average is $330.59 and its 200-day moving average is $333.57. Elevance Health, Inc. has a 12-month low of $273.71 and a 12-month high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings data on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.31 billion during the quarter, compared to the consensus estimate of $49.52 billion. During the same period last year, the firm earned $3.84 EPS. Elevance Health’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Sell-side analysts predict that Elevance Health, Inc. will post 33.96 earnings per share for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a $1.72 dividend. The ex-dividend date of this dividend is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a dividend yield of 2.4%. Elevance Health’s dividend payout ratio is 27.39%.

Analysts Set New Price Targets

Several research firms recently weighed in on ELV. Sanford C. Bernstein reduced their price target on shares of Elevance Health from $431.00 to $409.00 and set an “outperform” rating for the company in a research report on Friday, January 30th. JPMorgan Chase & Co. boosted their target price on shares of Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Barclays reduced their target price on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Weiss Ratings lowered shares of Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 2nd. Finally, Guggenheim lowered their price target on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $387.40.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.